$215 Million is the total value of Stonepine Capital Management, LLC's 25 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 46.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMYT | Sell | AMRYT PHARMA PLC - SPNR ADRsponsored ads | $44,025,000 | -16.0% | 6,298,348 | -0.6% | 20.48% | -5.8% |
| CTIC | Sell | CTI BIOPHARMA CORP | $21,977,000 | +0.5% | 3,681,195 | -21.4% | 10.22% | +12.7% |
| ADMA | Sell | ADMA BIOLOGICS INC | $13,860,000 | +6.2% | 7,000,000 | -1.8% | 6.45% | +19.1% |
| OPTN | Sell | OPTINOSE INC | $9,576,000 | +32.5% | 2,616,515 | -10.6% | 4.46% | +48.6% |
| OVID | Sell | OVID THERAPEUTICS INC | $7,499,000 | -43.4% | 3,487,928 | -17.3% | 3.49% | -36.5% |
| DMAC | Sell | DIAMEDICA THERAPEUTICS INC | $2,376,000 | -20.6% | 1,176,344 | -1.7% | 1.10% | -11.0% |
| SYBX | Sell | SYNLOGIC INC | $107,000 | -95.8% | 92,746 | -91.3% | 0.05% | -95.3% |
| CDTX | Sell | CIDARA THERAPEUTICS INC | $102,000 | -95.1% | 208,443 | -91.7% | 0.05% | -94.5% |
| NMTC | Exit | NEUROONE MEDICAL TECHNOLOGIE | $0 | – | -248,105 | -100.0% | -0.11% | – |
| CELC | Exit | CELCUITY INC | $0 | – | -239,433 | -100.0% | -0.93% | – |
| SRGA | Exit | SURGALIGN HOLDINGS INC | $0 | – | -7,375,678 | -100.0% | -0.93% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -586,224 | -100.0% | -2.73% | – |
| QDEL | Exit | QUIDEL CORP | $0 | – | -61,791 | -100.0% | -2.88% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -119,972 | -100.0% | -3.54% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -3,130,192 | -100.0% | -5.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.